{"url_path":"/sec/xbit/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 **","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1626878/0001171843-26-003419-index.html","accession_number":"0001171843-26-003419","cik":"0001626878","ticker":"XBIT","issuer_name":"XBiotech Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1626878/0001171843-26-003419-index.html","primary_entity_key":"0001626878","primary_entity_name":"XBiotech Inc."},"word_count":257,"has_tables":true,"body_markdown":"**Item 6.**\n\n**Exhibits.**\n\n \n\n[31.1](ex_956806.htm)\n\n[Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.](ex_956806.htm)\n\n \n\n \n\n[31.2](ex_956807.htm)\n\n[Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.](ex_956807.htm)\n\n \n\n \n\n[32.1](ex_956808.htm)\n\n[Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.](ex_956808.htm)\n\n \n \n\n101\n\nThe following financial statements from the XBiotech Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline Extensive Business Reporting Language (XBRL): (i) condensed consolidated balance sheets at March 31, 2026 and December 31, 2025, (ii) condensed consolidated statements of operations for the three months ended March 31, 2026 and 2025, (iii) condensed consolidated statements of shareholders’ equity for the three months ended March 31, 2026 and 2025; (iv) condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025 and (v) notes to condensed consolidated financial statements (detail tagged). \n\n \n \n\n104\n\nCover Page Interactive Data File (embedded within the iXBRL document).\n\n \n\n \n\n20\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: May 14, 2026\n\n \n\n**XBIOTECH INC.**\n\n \n\n \n\n \n\n \n\n \n \n\nBy:\n\n \n\n/S/ Sushma Shivaswamy\n\n \n\n \n\n \n\n \n\nSushma Shivaswamy\n\n \n\n \n\n \n\n \n\nInterim Chief Executive Officer and Chief Scientific Officer\n\n \n \n \n \n\n(Principal Executive Officer)\n\n \n \n \n \n \n\n \n\n \n\n \n\n \n\n \n\nDate: May 14, 2026\n\n \n\nBy:\n\n \n\n/S/ Angela Hu\n\n \n\n \n\n \n\n \n\nAngela Hu\n\n \n\n \n\n \n\n \n\n           Director of Finance\n\n \n \n \n\n \n\n           (Principal Financial Officer)\n\n \n\n \n\n21"}